Global Cycloplegic Agents Market – Industry Trends and Forecast to 2029

Cycloplegic Agents Market Analysis and Size

Cyclopentolate, a common cycloplegic agent, has a peak effect in 20 to 45 minutes and residual effects that last up to 36 hours (Cooper et al. 2000). Mild gastrointestinal discomfort and feeding intolerance are the most common side effects, but more severe atropine-like toxicity with symptoms ranging from vomiting, ileus, hyperthermia, delirium, and grand mal seizures have also been reported.

Data Bridge Market Research analyses that the cycloplegic agents market which is expected to reach at a healthy CAGR during the forecast period 2022 to 2029. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Cycloplegic Agents Market Scope and Segmentation  

Market Definition

Cycloplegic agents act by paralysing the iris's sphincter muscle, causing dilation, and by paralysing the ciliary muscle, which inhibits accommodation. Atropine, homatropine, scopolamine, cyclopentolate, and tropicamide are examples of cycloplegic agents. Preventing movement of the iris or ciliary body's dilator and sphincter muscles with cycloplegic drugs often relieves pain in inflammatory conditions such as uveitis and is a standard therapeutic procedure. Furthermore, as a result of the local release of prostaglandins, the iris usually constricts during irritation or inflammation. This makes it easier for adhesions to form with the lens. Cycloplegics also aid in the prevention of this complication.

Global Cycloplegic Agents Market Dynamics

Drivers

• Increasing cases of uveitis

Pediatric uveitis, which accounts for approximately 10-15% of all uveitis cases, presents unique diagnostic, follow-up, and treatment challenges. The insidious nature of uveitis in childhood, as well as paediatric patients' inability to adequately express their complaints and cooperate with eye examination, can cause a delay in diagnosis. More importantly, paediatric uveitis is more severe and often chronic. All these factors increase the likelihood of complications leading to vision loss. As a result, patients with refractory uveitis require paediatric rheumatology follow-up to begin systemic treatment and to detect underlying rheumatologic disease. These are the certain factors which propel the growth of the market.

• Rising Demand for Drugs

Three of the new parasympathomimetic-blocking agents appear to be effective cycloplegic drugs appropriate for refraction. These are disubstituted acetic acid esters (Treves and Testa, Ehrenberg, Ramp, Blanchard, and Treves). These drugs have been identified as cyclopentolate (Compound 75 GT), cyclopentolate (Compound 92 GT), and cyclopentolate (Compound 93 GT). Their use in 0.5% solution has previously been reported (cyclopentolate, by Priestley and Medine, and all three compounds by Gettes and Leopold and by Stolzer). Their cycloplegic efficiency appeared to be higher than homatropine but not quite as high as atropine. Furthermore, they have the benefit of a shorter duration of activity and the absence of local or systemic reactions.

Opportunities

• Rising usage of cycloplegic drugs

Cycloplegic drugs are muscarinic receptor blockers. Atropine, cyclopentolate, homatropine, scopolamine and tropicamide are among them. They are approved for use in cycloplegic refraction (paralysing the ciliary muscle to determine the true refractive error of the eye) and uveitis treatment. These are the factors which is expected to grow of the market.

Restraints/Challenges

• High cost of cycloplegic agents

High cost of cycloplegic agents and the low adoption rate in emerging and underdeveloped countries will obstruct the market's growth rate. The main disadvantages of cycloplegia are the patients' temporary symptoms of blurred vision and photophobia. The abolition of the accommodation response and an increase in ocular aberrations as a result of dilated pupils cause vision degradation.

This cycloplegic agents market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cycloplegic agents market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Cycloplegic Agents Market Scope

The cycloplegic agents market is segmented on the basis of mechanism of action, root, indication and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Mechanism of Action

• Atropine
• Cyclopentolate
• Cyclomidril
• Phenylephrine

 Root

• Oral
• Topical

 Indication

• Amblyopic Therapy
• Palliative Care for Phthisis
• Uveitis

 Distribution Channel

• Hospital
• Online
• Retail

Cycloplegic Agents Market Regional Analysis/Insights

The cycloplegic agents market is analysed and market size insights and trends are provided by country, mechanism of action, root, indication and distribution channel as referenced above.

The countries covered in the cycloplegic agents market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the cycloplegic agents market because of the presence of well-developed healthcare infrastructure and favourable reimbursement policies in the region.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 owing to the growing cases of uveitis. 

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The cycloplegic agents market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for cycloplegic agents market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the cycloplegic agents market. The data is available for historic period 2010-2020.

Competitive Landscape and Cycloplegic Agents Market Share Analysis

The cycloplegic agents market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to cycloplegic agents market.

Some of the major players operating in the cycloplegic agents market are:

• Pfizer Inc. (U.S.)
• Henry Schein, Inc (U.S.)
• Actiza Pharmaceutical Private Limited (India)
• hameln pharma gmbh (Germany)
• Sigma Pharmaceuticals, LLC (U.S.)
• Biomedica (India)
• Prudence Pharma Chem (India)
• Heer Pharma Pvt. Ltd. (India)
• Fresenius Kabi AG (Germany)

SKU-52437